The US Nuclear Regulatory Commission (NRC) has accepted the operating licence application for the medical isotope production facility, which Shine Medical Technologies is constructing in Janesville, Wisconsin. Shine expects to begin Mo-99 production in 2021, with commercial production due to start in 2022. Shine began construction in May and ongoing excavation at the site of the facility began in September. The next step in the construction process, concrete work, is expected to start later in October. The application seeks regulatory approval to operate non-reactor technology that will produce medical isotopes, including molybdenum-99 (Mo-99). The facility will be capable of supplying two-thirds of US patient demand for the isotope. NRC must now conduct a regulatory audit to determine a detailed schedule for the remainder of the review.